PARP1 and posterior cortical atrophy: Analyses of clinical samples demonstrated that PARP‐1 enzymatic activity is elevated as a function of PCa progression, and that high PARP‐1 activity strongly correlated with decreased progression‐free survival, implicated PARP‐1 as a driver of lethal malignant phenotypes.